Orchik D J, Shea J J, Ge N N
Shea Clinic, Memphis, Tennessee 38119, USA.
Am J Otol. 1998 Jul;19(4):478-82; discussion 483.
This study aimed to compare the summating potential and action potential ratio (SP:AP) in patients with Meniere's disease before and after various surgical and medical treatments as an indication of change in endolymphatic hydrops to study the progression of Meniere's disease.
The study design was a retrospective case review.
The study was conducted at an otology-neurotology referral center.
Eighty-eight ears of 84 patients with Meniere's disease received medical treatment in 18 ears and surgical treatments including endolymphatic shunt in 12 ears, streptomycin perfusion of the lateral semicircular canal in 9 ears, streptomycin perfusion of the middle ear in 33 ears, and dexamethasone perfusion of the middle ear in 16 ears.
Transtympanic electrocochleography (ECoG) was performed in all patients before treatment and 1-57 months after treatment (mean, 13.5 months) with a 2-year interval in 28 patients.
An enlarged SP:AP ratio (> or = 0.40) was used as the diagnostic criterion for endolymphatic hydrops.
Overall, an enlarged SP:AP ratio was found in 75% of ears before treatment and 78% after treatment. The SP:AP ratio, when enlarged, remained enlarged in 91% of ears. A nonenlarged SP:AP ratio before treatment became enlarged after treatment in 41% of ears. In American Academy of Otolaryngology-Head and Neck Surgery stage 1 Meniere's disease (pure-tone threshold average < or = 25 dB), an enlarged SP:AP was found in 58% of ears before treatment and 79% after. Twenty-five (89%) of 28 patients followed for 2 years were free of vestibular symptoms after treatment, and in 22 patients (79%), the SP:AP remained enlarged. The distribution of an enlarged SP:AP ratio was associated with the duration of disease (chi-square = 33.5552, p < 0.01).
The development of endolymphatic hydrops, as indicated by an enlarged SP:AP, is part of the progression of Meniere's disease. The longer the duration of the disease, the more likely the SP:AP ratio will be enlarged. These findings indicate that endolymphatic hydrops as detected by ECoG was not reversed in this study by the treatments used. Despite the absence of definitive spells of vertigo in most patients, endolymphatic hydrops as evidenced by an enlarged SP:AP ratio persisted.
本研究旨在比较梅尼埃病患者在接受各种手术和药物治疗前后的总和电位与动作电位比值(SP:AP),以此作为内淋巴积水变化的指标,来研究梅尼埃病的进展情况。
本研究设计为回顾性病例分析。
该研究在一家耳科 - 神经耳科转诊中心进行。
84例梅尼埃病患者的88只耳朵接受了治疗,其中18只耳朵接受了药物治疗,12只耳朵接受了包括内淋巴分流术在内的手术治疗,9只耳朵接受了后半规管链霉素灌注,33只耳朵接受了中耳链霉素灌注,16只耳朵接受了中耳地塞米松灌注。
所有患者在治疗前及治疗后1 - 57个月(平均13.5个月)进行了经鼓膜电耳蜗图(ECoG)检查,28例患者间隔2年进行复查。
以SP:AP比值增大(≥0.40)作为内淋巴积水的诊断标准。
总体而言,治疗前75%的耳朵SP:AP比值增大,治疗后为78%。SP:AP比值增大的耳朵中,91%在治疗后仍保持增大。治疗前SP:AP比值未增大的耳朵中,41%在治疗后增大。在美国耳鼻咽喉 - 头颈外科学会1期梅尼埃病(纯音平均听阈≤25 dB)患者中,治疗前58%的耳朵SP:AP比值增大,治疗后为79%。28例随访2年的患者中,25例(89%)治疗后无前庭症状,22例(79%)SP:AP比值仍增大。SP:AP比值增大的分布与病程有关(卡方 = 33.5552,p < 0.01)。
SP:AP比值增大所表明的内淋巴积水的发展是梅尼埃病进展的一部分。病程越长,SP:AP比值增大的可能性越大。这些发现表明,本研究中所用治疗方法未使ECoG检测到的内淋巴积水得到逆转。尽管大多数患者没有明确的眩晕发作,但SP:AP比值增大所证明的内淋巴积水仍然存在。